Overview
- UCLA researchers used a mild maternal immune activation in mice that produced lasting changes in offspring including chronic inflammation, slight brain overgrowth, miswired network connectivity, increased seizure risk, and autism-like behaviors.
- A single dose of the mTOR inhibitor rapamycin given to adult offspring produced broad improvements in neuronal firing, seizure susceptibility, network modularity, repetitive behavior, and sensory over-responsivity within about two hours.
- Gene-expression analysis showed rapamycin quickly reversed abnormal activity in genes tied to autism, epilepsy, and ion channels chiefly in excitatory neurons, indicating the drug acts by rebalancing neuronal excitability rather than repairing structural brain changes.
- The benefits were short-lived and daily dosing led to tolerance; together with rapamycin’s known toxicity and the limits of mouse-to-human translation, the authors say rapamycin itself is unsuitable for clinical use.
- Investigators frame the result as proof of concept that targeting mTOR signaling, excitatory/inhibitory balance, and sensory-network function could yield safer, symptom-focused treatments for specific autism features, but rigorous testing and new approaches are needed before any human application.